FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition for topical skin application contains corticosteroid representing halobetasol propionate in the concentration of less than 0.5% and a liquid oily component containing one or more esters of monocarboxylic and dicarboxylic acids. Esters of dicarboxylic acids are specified in a group consisting of diethylsebacate and diisopropyladipate. Esters of monocarboxylic acids are specified in a group consisting of isopropylmyristate and isopropylpalmitate. The concentration of the above liquid oily component makes from 1.5 to 3 times required to dissolve the amount of the corticosteroid in the composition at temperature 22°C±2°C completely, whereas the concentration of the esters in the liquid oily component makes at least 10% of the concentrations of the liquid oily component in the composition. What is also described is a method of treating a skin disorder.
EFFECT: invention provides reducing side effects of using halobetasol.
21 cl, 7 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
DELIVERY SYSTEM IN THE FORM OF GEL FOR LOCAL APPLICATION | 2001 |
|
RU2251410C2 |
PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION CONTAINING COMBINATION OF FUSIDIC ACID AND CORTICOSTEROID | 2008 |
|
RU2470645C2 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PHIMOSIS BY TOPICAL USING CORTICOSTEROID | 2001 |
|
RU2279893C2 |
TOPICAL COMPOSITIONS CONTAINING CORTICOSTEROID | 2016 |
|
RU2690659C2 |
METHOD FOR MAKING MICROEMULSIONS AND SUBMICRON EMULSIONS AND BASED COMPOSITION | 2005 |
|
RU2381023C2 |
STABLE DOSAGE FORM FOR LOCAL APPLICATION CONTAINING VORICONAZOLE | 2009 |
|
RU2472510C2 |
AEROSOL COMPOSITION CONTAINING COMBINATION OF CLOBETASOL PROPIONATE AND CALCITRIOL, ALCOHOLIC PHASE AND OIL PHASE | 2005 |
|
RU2384337C2 |
STABILISED COMPOSITION FOR TREATING PSORIASIS | 2009 |
|
RU2526162C2 |
PHARMACEUTICAL COMPOSITIONS INCLUDING COMBINATION OF CALCITRIOL AND CLOBESATOL PROPIONATE | 2003 |
|
RU2361594C2 |
APPLICATION OF COLOBETASOL-CONTAINING COMPOSITION FOR DISPERSION FOR TREATMENT OF PSORIASIS | 2006 |
|
RU2397769C2 |
Authors
Dates
2015-11-20—Published
2011-11-09—Filed